{"id":703146,"date":"2024-06-19T07:02:01","date_gmt":"2024-06-19T07:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=703146"},"modified":"2024-06-19T07:02:01","modified_gmt":"2024-06-19T07:02:01","slug":"methicillinresistant-staphylococcus-aureus-infections-pipeline-insights-clinical-trials-latest-approvals-therapies-key-players-pfizer-forest-laboratories-astrazeneca-cumberland-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/methicillinresistant-staphylococcus-aureus-infections-pipeline-insights-clinical-trials-latest-approvals-therapies-key-players-pfizer-forest-laboratories-astrazeneca-cumberland-pharma_703146.html","title":{"rendered":"Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights | Clinical Trials, Latest Approvals, Therapies, Key Players | Pfizer, Forest Laboratories, AstraZeneca, Cumberland Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1718703928.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights | Clinical Trials, Latest Approvals, Therapies, Key Players | Pfizer, Forest Laboratories, AstraZeneca, Cumberland Pharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1718703928.jpeg\" alt=\"Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights | Clinical Trials, Latest Approvals, Therapies, Key Players | Pfizer, Forest Laboratories, AstraZeneca, Cumberland Pharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cMethicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Insight, 2024\u201d report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Methicillin-Resistant Staphylococcus Aureus Infections &#8211; Pipeline Insight, 2024<\/a>,<\/strong>&rdquo; report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in Methicillin-Resistant Staphylococcus Aureus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">The Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">The Methicillin-resistant Staphylococcus Aureus Market is a critical sector within the healthcare industry dedicated to addressing the challenges posed by antibiotic-resistant strains of the bacterium Staphylococcus Aureus.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides detailed insights into the emerging therapies for the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and the aggregate therapies developed by major pharma companies.<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li>\n<p>It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Methicillin-resistant Staphylococcus aureus Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Methicillin-resistant Staphylococcus aureus (MRSA) is among the most formidable modern pathogens. This bacterium, which can live harmlessly as a commensal organism and spread in both healthcare and community environments, is a major cause of bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections. MRSA&#8217;s genetic diversity is marked by the continuous emergence of epidemic strains. Although its incidence has recently declined in some areas, MRSA continues to present a significant clinical challenge, maintaining high levels of morbidity and mortality. Effective treatment remains difficult, necessitating the use of novel antimicrobials and additional care measures, such as infectious disease consultations, echocardiography, and source control.<\/p>\n<p style=\"text-align: justify;\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report covers the emerging products under different phases of clinical development like &ndash;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Methicillin-Resistant Staphylococcus Aureus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>intravenous<\/p>\n<\/li>\n<li>\n<p>Subcutaneous<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Products have been categorized under various Molecule types, such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal Antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Methicillin-Resistant Staphylococcus Aureus Infections Therapeutic Segment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Methicillin-Resistant Staphylococcus Aureus Infections Emerging Drugs<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>HY-004B8b: Helperby Therapeutics<\/p>\n<\/li>\n<li>\n<p>TRL1068: Trellis Bioscience<\/p>\n<\/li>\n<li>\n<p>Delpazolid (LCB01-0371): LegoChem Biosciences<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>There are approx. 25+ key companies developing therapies for Methicillin-Resistant Staphylococcus Aureus Infections<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The Leading Companies in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Trellis Bioscience<\/p>\n<\/li>\n<li>\n<p>LegoChem Biosciences<\/p>\n<\/li>\n<li>\n<p>Aptorum Group<\/p>\n<\/li>\n<li>\n<p>ContraFect<\/p>\n<\/li>\n<li>\n<p>Crystalgenomics<\/p>\n<\/li>\n<li>\n<p>Cellics Therapeutics<\/p>\n<\/li>\n<li>\n<p>MicuRx<\/p>\n<\/li>\n<li>\n<p>Oxford Antibiotic Group<\/p>\n<\/li>\n<li>\n<p>Destiny Pharma<\/p>\n<\/li>\n<li>\n<p>TSRL, Inc.<\/p>\n<\/li>\n<li>\n<p>TAXIS Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Basilea Pharmaceutica<\/p>\n<\/li>\n<li>\n<p>Helperby Therapeutics<\/p>\n<\/li>\n<li>\n<p>Akagera Medicines<\/p>\n<\/li>\n<li>\n<p>Histogen<\/p>\n<\/li>\n<li>\n<p>Alphamab Co. Ltd<\/p>\n<\/li>\n<li>\n<p>Biocidium Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/methicillin-resistant-staphylococcus-aureus-mrsa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=methicillinresistant-staphylococcus-aureus-infections-pipeline-insights-clinical-trials-latest-approvals-therapies-key-players-pfizer-forest-laboratories-astrazeneca-cumberland-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=methicillinresistant-staphylococcus-aureus-infections-pipeline-insights-clinical-trials-latest-approvals-therapies-key-players-pfizer-forest-laboratories-astrazeneca-cumberland-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Methicillin-resistant Staphylococcus Aureus Infections Pipeline Insights \u201cMethicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Insight, 2024\u201d report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market. DelveInsight&rsquo;s, &ldquo;Methicillin-Resistant &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/methicillinresistant-staphylococcus-aureus-infections-pipeline-insights-clinical-trials-latest-approvals-therapies-key-players-pfizer-forest-laboratories-astrazeneca-cumberland-pharma_703146.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-703146","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=703146"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/703146\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=703146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=703146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=703146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}